178 related articles for article (PubMed ID: 15921858)
21. COX-2 inhibitors--is there cause for concern?
Seibert K; Lefkowith J; Tripp C; Isakson P; Needleman P
Nat Med; 1999 Jun; 5(6):621-2. PubMed ID: 10371498
[No Abstract] [Full Text] [Related]
22. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
Wu R; Abramson AL; Shikowitz MJ; Dannenberg AJ; Steinberg BM
Clin Cancer Res; 2005 Sep; 11(17):6155-61. PubMed ID: 16144915
[TBL] [Abstract][Full Text] [Related]
23. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
[TBL] [Abstract][Full Text] [Related]
24. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
25. [The role of cyclooxygenase and prostaglandins in the pathogenesis of rheumatoid arthritis].
Stańczyk J; Kowalski ML
Pol Merkur Lekarski; 2001 Nov; 11(65):438-43. PubMed ID: 11852819
[TBL] [Abstract][Full Text] [Related]
26. The molecular pathogenesis of cholangiocarcinoma.
Berthiaume EP; Wands J
Semin Liver Dis; 2004 May; 24(2):127-37. PubMed ID: 15192786
[TBL] [Abstract][Full Text] [Related]
27. Defining COX-2 inhibitors.
Lipsky PE
J Rheumatol Suppl; 2000 Oct; 60():13-6. PubMed ID: 11032097
[TBL] [Abstract][Full Text] [Related]
28. Cyclooxygenase as a target in lung cancer.
Brown JR; DuBois RN
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4266s-4269s. PubMed ID: 15217972
[TBL] [Abstract][Full Text] [Related]
29. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis.
Milas L
Am J Clin Oncol; 2003 Aug; 26(4):S66-9. PubMed ID: 12902859
[TBL] [Abstract][Full Text] [Related]
30. Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
Okajima E; Uemura H; Ohnishi S; Tanaka M; Ohta M; Tani M; Fujimoto K; Ozono S; Okajima E; Hirao Y
Aktuelle Urol; 2003 Jul; 34(4):256-8. PubMed ID: 14566678
[TBL] [Abstract][Full Text] [Related]
31. Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?
Koga H
Cancer; 2003 Aug; 98(4):661-7. PubMed ID: 12910508
[TBL] [Abstract][Full Text] [Related]
32. Expression of cyclooxygenase-2 in cholangiocarcinoma: correlation with clinicopathological features and prognosis.
Kim HJ; Lee KT; Kim EK; Sohn TS; Heo JS; Choi SH; Choi DI; Lee JK; Paik SW; Rhee JC
J Gastroenterol Hepatol; 2004 May; 19(5):582-8. PubMed ID: 15086604
[TBL] [Abstract][Full Text] [Related]
33. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review).
Badawi AF; Badr MZ
Int J Oncol; 2002 Jun; 20(6):1109-22. PubMed ID: 12011987
[TBL] [Abstract][Full Text] [Related]
34. Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence.
Müller-Decker K
Cancer Metastasis Rev; 2011 Dec; 30(3-4):343-61. PubMed ID: 22038018
[TBL] [Abstract][Full Text] [Related]
35. COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.
Saha D; Pyo H; Choy H
Am J Clin Oncol; 2003 Aug; 26(4):S70-4. PubMed ID: 12902860
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview.
Famaey JP
Inflamm Res; 1997 Nov; 46(11):437-46. PubMed ID: 9427063
[TBL] [Abstract][Full Text] [Related]
37. Current application of selective COX-2 inhibitors in cancer prevention and treatment.
Stratton MS; Alberts DS
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):37-51. PubMed ID: 12102579
[TBL] [Abstract][Full Text] [Related]
38. Akt expression may predict favorable prognosis in cholangiocarcinoma.
Javle MM; Yu J; Khoury T; Chadha KS; Iyer RV; Foster J; Kuvshinoff BW; Gibbs JF; Geradts J; Black JD; Brattain MG
J Gastroenterol Hepatol; 2006 Nov; 21(11):1744-51. PubMed ID: 16984600
[TBL] [Abstract][Full Text] [Related]
39. Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference.
Sirica AE; Nathanson MH; Gores GJ; Larusso NF
Hepatology; 2008 Dec; 48(6):2040-6. PubMed ID: 18855901
[TBL] [Abstract][Full Text] [Related]
40. Potential role of selective COX-2 inhibitors in cancer management.
Dang CT; Shapiro CL; Hudis CA
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):30-6. PubMed ID: 12102578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
